Company intelligence / Profile preview

ToxGenSolutions B.V.

Ownership: Private
Development stage: Preclinical

Overview

The company develops preclinical diagnostic tools using advanced biomarker and genetic signature technologies to identify individuals at risk of late-onset Alzheimer’s Disease. Their approach enables earlier intervention by healthcare professionals but there are no reported clinical trial results as the focus is on diagnostics rather than therapeutics.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: (epi-)genetic diagnosticsbiomarkers
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on ToxGenSolutions B.V..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ToxGenSolutions B.V..

Explore the full profile